Abstract: An antibody having a higher function targeting a CD73 antigen, and more specifically, an antibody for cancer treatment having a higher activity. The antibody or a human-type antibody derivative that has a binding activity to a CD73 antigen and activates T cells having a toxic activity to cancer cells, and includes complementarity determining regions of any combination of heavy and light chains each having a specific amino acid sequence.

Abstract: An alkali metal-sulfur-based secondary battery, in which coulombic efficiency is improved by suppressing a side reaction during charge, and a reduction in discharge capacity by repetition of charge and discharge is suppressed and which has a long battery life and an improved input/output density, includes a positive electrode or a negative electrode containing a sulfur-based electrode active material; an electrolyte solution containing an ether compound such as THF and glyme and a solvent such as a fluorine-based solvent, wherein at least a part of the ether compound and the alkali metal salt forms a complex; and a counter electrode.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: An alkali metal-sulfur-based secondary battery, in which coulombic efficiency is improved by suppressing a side reaction during charge, and a reduction in discharge capacity by repetition of charge and discharge is suppressed and which has a long battery life and an improved input/output density, includes a positive electrode or a negative electrode containing a sulfur-based electrode active material; an electrolyte solution containing an ether compound such as THF and glyme and a solvent such as a fluorine-based solvent, wherein at least a part of the ether compound and the alkali metal salt forms a complex; and a counter electrode.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: The present invention provides a method of selectively augmenting an immunosuppressive function in various functions of NKT cells, and a method of efficiently inducing an antigen specific immunosuppression in vivo, as well as a pharmaceutical obtained by applying the same. More particularly, the present invention provides a pharmaceutical (e.g., a preventive or therapeutic agent for immune diseases such as allergic disease and autoimmune disease) containing a CD1d ligand and a target antigen (e.g., allergen, autoantigen). Preferably, the pharmaceutical contains a drug delivery vehicle including the CD1d ligand and the target antigen and having a lumen.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.